JME
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Accepted Preprint first posted online on 10 February 2009

Journal of Molecular Endocrinology 2009;42:461.

Journal of Molecular Endocrinology (2009) In press  DOI: 10.1677/JME-09-0009
© 2009 Society for Endocrinology

This Article
Right arrow Accepted manuscript (PDF)
Right arrow All Versions of this Article:
JME-09-0009v1
JME-09-0009v2
42/6/461    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dudley, K.
Right arrow Articles by Farrell, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dudley, K.
Right arrow Articles by Farrell, W.

Review

Pituitary tumours: all silent on the epigenetics front

Kevin Dudley, Kate Revill, Richard Clayton and William Farrell

K Dudley, ISTM, University of Keele, Stoke-on-Trent, United Kingdom
K Revill, ISTM, University of Keele, Stoke-on-Trent, United Kingdom
R Clayton, Dept of Medicine, University of Keele, North Staffordshire Hospital Centre, stoke, United Kingdom
W Farrell, Medical research unit, Keele University, Stoke-on-Trent, ST4 7QB, United Kingdom

Correspondence: William Farrell, Email: w.e.farrell{at}keele.ac.uk

Abstract

Investigation of the epigenome of sporadic pituitary tumours is providing a more detailed understanding of aberrations that characterise this tumour type. Early studies, in this and other tumour types adopted candidate-gene approaches to characterise CpG island methylation as a mechanism responsible for or associated-with gene silencing. However, more recently, investigators have adopted approaches that do not require <i>a priori</i> knowledge of the gene and or transcript, as example differential display techniques, and also genome-wide, array based approaches, to <i>uncover</i> or <i>unmask</i> silenced genes. Furthermore, through use of chromatin immunoprecipitation (ChIP) as a selective enrichment techniques, we are now beginning to identify modifications that target the underlying histones themselves and that have roles in gene silencing events. Collectively, these studies provided convincing evidence that change to the tumour epigenome are not simply epiphenomena but have functional consequences in the context of pituitary tumour evolution. Our ability to perform these types of studies has been and is increasingly reliant upon technological advances in the genomics and epigenomics arena. In this context, other more recent advances and developing technologies, and in particular, next generation or flow cell re-sequencing techniques offer exciting opportunities for our future studies of this tumour type.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2009 by the Society for Endocrinology.